ALISO VIEJO, Calif. – September 18, 2012 – Sequent Medical, Inc. announced today the award by the U.S. Patent and Trademark Office of Patent No. 8,261,648, entitled "Braiding Mechanism and Method of Use."

The company has developed proprietary MicroBraid™ technology to create the WEB® Aneurysm Embolization System. MicroBraid technology allows the fabrication of fine wire braided devices, such as the WEB, that optimize key properties of porosity, radial compliance, and collapsed profile.

Building on the experience with endovascular embolic coils, the WEB enables physicians to treat intracranial aneurysms with the familiarity of an intra-saccular approach using established biomaterials. The WEB is designed to bridge the aneurysm neck and to promote rapid peri-procedural stasis in both ruptured and un-ruptured aneurysms. The initial WEB configurations offer a treatment alternative for wide-necked bifurcation aneurysms, which are among the more difficult aneurysms to treat using other endovascular approaches.

"We are pleased to have achieved this important milestone in our ongoing efforts to develop our intellectual property portfolio," said Tom Wilder, President & CEO of Sequent Medical. "The utility of this patented braiding technology extends beyond the neurovascular field, and has the potential to address a number of unmet clinical needs."

About Sequent Medical, Inc.
Sequent Medical, Inc. (www.sequentmedical.com) is a privately held medical-device company that is dedicated to the development of innovative catheter-based neurovascular technologies. The WEB Aneurysm Embolization System has received the CE mark, and is approved for use in several regions in addition to Europe. It is not available for either investigational or commercial use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany. Sequent licensed its MicroBraid technology to Inceptus Medical LLC for use in select cardiovascular medical device applications.